PSIL news

AdvisorShares Psychedelics

Stories about this fund's companies, ranked by fund weight and recency. Times are local.

Yahoo! Finance · 28 Oct 2026, 07:29 UTC
The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie
7.8% of PSIL
wallstreet:online · 27 Oct 2026, 10:30 UTC
Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026
11.5% of PSIL
Yahoo! Finance · 28 Oct 2026, 16:03 UTC
This Dividend Powerhouse Is Heading Into Q3 Earnings With Plenty at Stake
4.1% of PSIL
Financial Post · 26 Oct 2026, 00:00 UTC
Definium Therapeutics Announces New Employee Inducement Grants
12.9% of PSIL
Where to buy PSIL
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
Seeking Alpha · 28 Oct 2026, 08:28 UTC
AbbVie: Still Strong Growth, But Patent Cliff Getting Closer (NYSE:ABBV) | Seeking Alpha
4.1% of PSIL
Investing.com · 26 Oct 2026, 18:39 UTC
B.Riley reiterates Buy on Compass Pathways stock, $22 target By Investing.com
11.5% of PSIL
Where to buy PSIL
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
CNBC · 27 Oct 2026, 18:00 UTC
I just bought this pharma stock for its next generation of blockbuster drugs -- and its dividend
4.1% of PSIL
Yahoo! Finance · 27 Oct 2026, 14:32 UTC
Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings
4.1% of PSIL
Market Screener · 27 Oct 2026, 14:07 UTC
AbbVie Submits Biologics License Application For Etentamig To U.S. Food And Drug Administration For Adults With Relapsed Or Refractory Multiple Myeloma
4.1% of PSIL
RTTNews · 27 Oct 2026, 13:33 UTC
AbbVie Submits FDA Application For Etentamig In Multiple Myeloma
4.1% of PSIL
Yahoo! Finance · 27 Oct 2026, 18:07 UTC
Johnson & Johnson (JNJ) Stock Trades At A Discount Following Its 97% Run
3.6% of PSIL
Yahoo! Finance · 27 Oct 2026, 15:16 UTC
4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential
3.6% of PSIL
Yahoo! Finance · 27 Oct 2026, 14:00 UTC
CDs or Dividend Stocks: Which Pays Retirees Better Right Now?
3.6% of PSIL
wallstreet:online · 27 Oct 2026, 11:30 UTC
Johnson & Johnson to Host Enterprise Business Review
3.6% of PSIL
Market Screener · 26 Oct 2026, 16:36 UTC
Neurocrine Biosciences, Inc. Presents New Analysis Establishing Benchmark For Clinically Meaningful Change In Overall Health Reported By Patients With Tardive Dyskinesia Treated With INGREZZA
4.4% of PSIL
firstwordpharma.com · 26 Oct 2026, 19:22 UTC
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer
3.6% of PSIL
Yahoo! Finance · 26 Oct 2026, 19:12 UTC
What Do Johnson & Johnson (JNJ) Cancer Trial Wins Mean For Its Stock?
3.6% of PSIL
24/7 Wall St. · 26 Oct 2026, 11:51 UTC
AbbVie Options Price In a Sudden 5% Swing -- What Investors Must Know Before Oct. 30
4.1% of PSIL
Yahoo! Finance · 26 Oct 2026, 06:50 UTC
Billionaire Ken Griffin Is Buying This Dividend King That Wall Street Still Rates a Buy
4.1% of PSIL
Investing.com · 26 Oct 2026, 10:25 UTC
Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial By Reuters
3.6% of PSIL